33P - Preclinical development of adoptive cell therapy with tumor-infiltrating lymphocytes for patients with renal cell carcinoma

Date 20 November 2015
Event ESMO Symposium on Immuno-Oncology 2015
Session Welcome reception and general Poster viewing
Topics Renal Cell Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Rikke Andersen
Citation Annals of Oncology (2015) 26 (suppl_8): 5-14. 10.1093/annonc/mdv514
Authors R. Andersen1, M.C.W. Westergaard2, J.W. Kjeldsen2, M. Donia1, I.M. Svane1
  • 1Department Of Hematology And Department Of Oncology, Center for Cancer Immune Therapy, 2730 - Copenhagen/DK
  • 2Department Of Hematology, Center for Cancer Immune Therapy, 2730 - Copenhagen/DK



Adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TILs) achieved impressive clinical results with response rates of up to 50% in patients with metastatic melanoma.

Previous trials investigating TIL therapy for patients with renal cell carcinoma (RCC) have shown limited success, however none of these early trials used current TIL manufacturing methods and preparative chemotherapy regimens. RCC is an obvious candidate for implementation of TIL therapy because of its known immunogenicity.


Primary tumor lesions from 35 patients with RCC scheduled for radical or partial nephrectomy at the dept. of Urology, Herlev Hospital are being collected. TIL cultures are established with current manufacturing methods including high-doses of IL-2 and a standard two-step expansion process. Autologous tumor cell lines are grown from corresponding tumor specimens used to isolate and expand TILs.


The study is ongoing. TIL cultures were efficiently generated and expanded from 16 of 16 tumor specimens. TILs contained >95% T cells with a considerably variable CD4/CD8 ratio. Short-term cultured autologous tumor cell lines were established from 10 of 16 patients. Functional TILs with specific production of cytokines or mobilization of CD107a after recognition of autologous tumor antigens were identified in 7 patients (70%).


TILs from RCC specimens can be isolated, activated and expanded to numbers sufficient for ACT and the majority display tumor-recognition in vitro. This study paves the way for clinical testing of ACT in patients with metastatic RCC.

Clinical trial identification


All authors have declared no conflicts of interest.